98%
921
2 minutes
20
This paper introduces EmotionTFN (Emotion-Multi-Scale Temporal Fusion Network), a novel hierarchical temporal fusion architecture that addresses key challenges in IoT emotion recognition by processing diverse sensor data while maintaining accuracy across multiple temporal scales. The architecture integrates physiological signals (EEG, PPG, and GSR), visual, and audio data using hierarchical temporal attention across short-term (0.5-2 s), medium-term (2-10 s), and long-term (10-60 s) windows. Edge computing optimizations, including model compression, quantization, and adaptive sampling, enable deployment on resource-constrained devices. Extensive experiments on MELD, DEAP, and G-REx datasets demonstrate 94.2% accuracy on discrete emotion classification and 0.087 mean absolute error on dimensional prediction, outperforming the best baseline (87.4%). The system maintains sub-200 ms latency on IoT hardware while achieving a 40% improvement in energy efficiency. Real-world deployment validation over four weeks achieved 97.2% uptime and user satisfaction scores of 4.1/5.0 while ensuring privacy through local processing.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390569 | PMC |
http://dx.doi.org/10.3390/s25165066 | DOI Listing |
Med Phys
September 2025
Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China.
Background: Four-dimensional magnetic resonance imaging (4D-MRI) holds great promise for precise abdominal radiotherapy guidance. However, current 4D-MRI methods are limited by an inherent trade-off between spatial and temporal resolutions, resulting in compromised image quality characterized by low spatial resolution and significant motion artifacts, hindering clinical implementation. Despite recent advancements, existing methods inadequately exploit redundant frame information and struggle to restore structural details from highly undersampled acquisitions.
View Article and Find Full Text PDFIEEE Trans Neural Syst Rehabil Eng
September 2025
Force prediction is crucial for functional rehabilitation of the upper limb. Surface electromyography (sEMG) signals play a pivotal role in muscle force studies, but its non-stationarity challenges the reliability of sEMG-driven models. This problem may be alleviated by fusion with electrical impedance myography (EIM), an active sensing technique incorporating tissue morphology information.
View Article and Find Full Text PDFIEEE J Biomed Health Inform
September 2025
Positron Emission Tomography (PET) is a critical imaging modality in nuclear medicine but requires radioactive tracer administration, which increases radiation exposure risks. While recent studies have investigated MR-guided low-dose PET denoising, they neglect two critical factors: the synergistic roles of multicontrast MR images and disease-specific denoising requirements. In this work, we propose a diffusion model that integrates T1-weighted, T2 fluid attenuated inversion recovery (T2 FLAIR), and hippocampal-optimized (T2 HIPPO) MR sequences to achieve ultra-low-dose PET denoising tailored for temporal lobe epilepsy (TLE).
View Article and Find Full Text PDFBiomed Eng Lett
September 2025
Department of Cardiovascular Ultrasound, The First Hospital of China Medical University, Shenyang, China.
Abstract: Hypertrophic cardiomyopathy (HCM) is a common hereditary heart disease and is the leading cause of sudden cardiac death in adolescents. Septal hypertrophy (SH) and apical hypertrophy (AH) are two common types. The former is characterized by abnormal septal myocardial thickening and the latter by left ventricular apical hypertrophy, both of which significantly increase the risk of heart failure, arrhythmias, and other serious complications.
View Article and Find Full Text PDFTransl Oncol
September 2025
Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan; Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan. Electronic address:
Liquid biopsies, particularly those involving circulating tumor DNA (ctDNA) from patient blood, have emerged as crucial and minimally invasive adjuncts to standard tissue-based testing. ctDNA testing enables the identification of actionable mutations for targeted therapy and can be routinely used when tissue samples are unavailable for genotyping. Compared to tissue-based testing, ctDNA testing has the advantages of capturing spatial or temporal genomic heterogeneity and facilitating repeated assessments.
View Article and Find Full Text PDF